Phase II data for G1’s trilaciclib raises questions about its uptake potential in TNBC

G1 showed trilaciclib led to a significant reduction in the risk of death for metastatic triple-negative breast cancer, but a shifting treatment landscape that includes checkpoint inhibitors could mean an uncertain commercial and regulatory path as the biotech plans its Phase III trial. Investors trimmed $419.9 million off of G1’s market cap as they digested the results.

In a controlled, open-label Phase II study of trilaciclib plus chemotherapy, the

Read the full 697 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE